Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The Oxford Epilepsy Research Group is at the forefront of some potentially ground-breaking work with patients who have drug-resistant epilepsy. Epilepsy affects over 50 million people worldwide and nearly one in three people with epilepsy are resistant to current drugs.

Clinical epileptology team

In August 2018, LivaNova PLC launched a global registry to evaluate the use of its Vagus Nerve Stimulation Therapy® (VNS Therapy) System for patients with drug-resistant epilepsy.

The system consists of two implantable components: a programmable electronic pulse generator that is connected to a bipolar electrical lead, which sends mild pulses to stimulate the vagus nerve at regular intervals throughout the day.

This study will enroll up to 2,000 patients and follow them for five years. The analysis of the data from this large repository will help to evaluate the safety and effectiveness of this therapy, as well as clinical outcomes for patients.

The Oxford Epilepsy Research Group, led by Arjune Sen, enrolled the first patient in Europe to the trial, and has recruited the largest number of patients to the study so far, along with Child Neurology Consultants Austin, Dr Keough.

Child Neurology Consultants Austin, Dr. Keough​